Profile data is unavailable for this security.
About the company
Shanghai MicuRx Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development (R&D) and commercialization of innovative drugs. The Company's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The Company also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The Company operates its businesses primarily in the domestic market.
- Revenue in CNY (TTM)120.07m
- Net income in CNY-467.96m
- Incorporated2012
- Employees205.00
- LocationShanghai MicuRx Pharmaceutical Co LtdSHANGHAI 201210ChinaCHN
- Phone+86 2 150900550
- Fax+86 2 161101898
- Websitehttp://www.micurxchina.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ChengDu Sheng Nuo Biotec Co Ltd | 481.63m | 92.49m | 3.49bn | 1.13k | 37.61 | 3.80 | -- | 7.24 | 0.8279 | 0.8279 | 4.31 | 8.20 | 0.3401 | 0.862 | 3.96 | 426,977.70 | 6.52 | 7.47 | 8.67 | 9.44 | 59.92 | 70.52 | 19.17 | 15.82 | 0.8466 | 13.35 | 0.32 | 21.83 | 9.93 | 9.37 | 9.08 | 18.69 | 54.71 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 120.07m | -467.96m | 3.58bn | 205.00 | -- | 6.30 | -- | 29.80 | -0.7142 | -0.7142 | 0.1833 | 0.8664 | 0.1067 | 0.623 | 4.76 | 585,689.70 | -41.57 | -- | -45.49 | -- | 81.88 | -- | -389.75 | -- | 6.43 | -- | 0.3488 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 2.19bn | 50.41m | 3.89bn | 1.43k | 80.53 | 1.72 | -- | 1.77 | 0.0944 | 0.0944 | 4.11 | 4.41 | 0.6831 | 4.89 | 5.41 | 1,538,342.00 | 1.61 | -0.6002 | 2.02 | -0.7417 | 46.46 | 56.64 | 2.35 | -0.9128 | 2.46 | 23.86 | 0.0908 | -- | -2.00 | 4.79 | 17.41 | -11.68 | -25.97 | -- |
Data as of Nov 14 2024. Currency figures normalised to Shanghai MicuRx Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
11.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 21.60m | 6.25% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 6.65m | 1.93% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2024 | 4.87m | 1.41% |
| CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 2024 | 3.75m | 1.09% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 2.99m | 0.87% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 684.29k | 0.20% |
| CPIC Fund Management Co. Ltd.as of 30 Jun 2024 | 272.49k | 0.08% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 200.00k | 0.06% |
| Changsheng Fund Management Co., Ltd.as of 30 Jun 2024 | 170.27k | 0.05% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 135.90k | 0.04% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
